Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer | Latest News RSS feed

Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer - Latest News


Penfluridol overcomes paclitaxel resistance in metastatic breast cancer

Paclitaxel is a first line chemotherapeutic agent for the patients with metastatic ... Our study also provides convincing results to establish a combination therapy of PFL with paclitaxel for the ... read more

Study: Drug, chemo combo double survival in metastatic lung cancer

April 17 (UPI) --Combining the immunotherapy drug pembrolizumab with chemotherapy doubled survival in patients with some forms of lung cancer compared with chemo alone, according to an international ... read more

Alimta Approval for Frontline Keytruda / Chemo Combo in NSCLC Gets Expansion

The FDA expanded the indication for for Alimta (pemetrexed) injection plus Keytruda (pembrolizumab) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous ... read more

Looking for another news?


Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

This new lung cancer medicine was approved in ... The studies include double/triple combination studies for chemotherapy and targeted therapies and several avelumab combination therapies with ... read more


FDA Approvals in Bladder Cancer and NSCLC, and 2019 ELCC Highlights

FDA approvals in bladder cancer and ... initial overall survival analysis of the study of first-line durvalumab alone or in combination with tremelimumab versus platinum-based chemotherapy in patients ... read more

Cancer: Highly personalized therapy can improve outcomes

The findings of a new study suggest that people who receive highly personalized combination therapy for treatment-resistant cancer can experience improved disease control and survival rates ... ... read more

Combining Trial Data With Clinical Case Studies to Illustrate the Lung Cancer Landscape

In a discussion at the 2019 Spring Session of the Florida Society of Clinical Oncology, speakers provided updates to the treatment ... free and overall survival in refractory non­–small cell lung ... read more

First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer: Study

The combination of immune checkpoint inhibitors and chemotherapy has been successfully tested in different trials as first line therapy for metastatic non-small cell lung cancer ... survival or ... read more

Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group

It is now approved, as a monotherapy, for first-line treatment of patients with stage III or metastatic non-small cell lung cancer ... study approved to be included in Keytruda’s label, the drug ... read more

Keytruda continues its lung cancer land grab with another FDA nod

Solo therapy with Merck & Co.’s Keytruda is already approved in previously untreated non-small cell lung cancer ... treatment for metastatic NSCLC patients whose tumors express PD-L1, but with no EGFR ... read more

Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC

The initial overall survival ... alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC), may have been ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us